Industry development agreement for innovative eye syringe

Morten C. Moe (left) and Jan Teje Andersen
Morten C. Moe (left) and Jan Teje Andersen

The Department of Ophthalmology at Oslo University Hospital and the Laboratory of Adaptive Immunity and Homeostasis of both Oslo University Hospital and University of Oslo, have entered an industry development agreement with the Dutch medical device company SJJ Solutions. The collaboration has resulted in a prototype of a tailor-made syringe optimised for eye injections.

Researchers at The Laboratory of Adaptive Immunity and Homeostasis are currently documenting that the syringe possesses optimal features for storage and shelf-life with and without anti-VEGF inhibitors. 

Main article published on the inven2 home page:
SJJ solutions signs industry develompment agreement with inven2

From the article:

Professor Morten C. Moe, Head of Research at Division for Head, Neck and Reconstructive surgery and at the Department of Ophthalmology at Oslo University Hospital, commented:
“The syringe the team has developed provides ophthalmologists with an optimal tool for treating patients needing regular eye injections. At our Department of Ophthalmology, we give approximately 30.000 anti-VEGF injections to 4000 patients each year. This number will increase as the population gets older”.

Head of The Laboratory of Adaptive Immunity and Homeostasis at Oslo University Hospital and University of Oslo, Jan Terje Andersen, commented,
“We are very excited to be part of this industry collaboration with SJJ Solutions together with Morten Moe, Magne Sivertsen, Øystein Jørstad and the rest of their colleagues at the Department of Ophthalmology. It is great that our in-depth research and knowledge about antibodies can provide this much needed product with the required quality measures and documentation.”

 
Page visits: 148